10 completed. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer Durvalumab, Olaparib - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative | Phase 1 | Completed | OHSU Knight Cancer Institute | 3 | 2018-05-03 | 2020-11-20 |
| IACS-010759 in Advanced Cancers Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2017-11-13 | 2020-11-24 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Galunisertib, Laboratory Biomarker Analysis, Paclitaxel - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 29 | 2016-03-01 | 2023-11-22 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 | Completed | Mayo Clinic | 12 | 2013-04-09 | 2023-02-14 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2012-08-21 | 2018-03-30 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 22 | 2011-01-01 | 2015-05-25 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery Cilengitide, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2016-03-15 |
| Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2010-06-01 | 2017-12-22 |
| Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Laboratory Biomarker Analysis, Pharmacological Study, Veliparib - Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 98 | 2009-04-20 | 2018-06-29 |
Triple Negative Breast Neoplasms (10) · Breast Neoplasms (8) · Breast Neoplasms, Male (4) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Breast Carcinoma In Situ (1) · Hereditary Breast and Ovarian Cancer Syndrome (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Breast Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms by Histologic Type (3) · Adnexal Diseases (2) · Breast Neoplasms (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2)
Paclitaxel (4) · Taxes (4) · veliparib (3) · Doxorubicin (2) · Carboplatin (1) · Celecoxib (1) · Cilengitide (1) · Cyclophosphamide (1) · Disulfides (1) · Epirubicin (1) · IACS-010759 (1) · Immunoglobulin G (1) · Interferon alpha-2 (1) · Introns (1) · LY-2157299 (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Vanderbilt-Ingram Cancer Center (1)
United States (10)
Shannon Puhalla (2) · Bhavana Pothuri (1) · Julian Molina (1) · Scott Okuno (1) · Shipra Gandhi (1) · Stacy Moulder (1) · Timothy A Yap (1) · Vandana Abramson, MD (1) · Zahi Mitri, MD, MS (1)
PMID 25947565, PMID 32379297, PMID 36658425
P30CA016672 (2), P30CA047904 (2), U01CA099168 (2), N01CM62204 (1), P30CA013330 (1), P30CA015083 (1), P30CA068485 (1), R01CA152228 (1), U01CA062461 (1), U01CA062505 (1), U01CA069912 (1), U01CA132194 (1), UL1TR001412 (1), UM1CA186690 (1), UM1CA186716 (1)